Palisade Operating Cycle from 2010 to 2026

PALI Stock  USD 1.68  0.05  2.89%   
Palisade Bio's Operating Cycle is decreasing with stable movements from year to year. Operating Cycle is predicted to flatten to 236.07. For the period between 2010 and 2026, Palisade Bio, Operating Cycle quarterly trend regression had mean deviation of  623.53 and range of 4.4 K. View All Fundamentals
 
Operating Cycle  
First Reported
2010-12-31
Previous Quarter
248.49
Current Value
236.07
Quarterly Volatility
1.1 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Palisade Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Palisade Bio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.6 K, Interest Expense of 13.1 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 17.64, Dividend Yield of 0.0 or PTB Ratio of 0.29. Palisade financial statements analysis is a perfect complement when working with Palisade Bio Valuation or Volatility modules.
  
Build AI portfolio with Palisade Stock
Check out the analysis of Palisade Bio Correlation against competitors.
For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.
The Operating Cycle trend for Palisade Bio offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Palisade Bio is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Palisade Bio's Operating Cycle Growth Pattern

Below is the plot of the Operating Cycle of Palisade Bio over the last few years. It is Palisade Bio's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Palisade Bio's overall financial position and show how it may be relating to other accounts over time.
Operating Cycle10 Years Trend
Pretty Stable
   Operating Cycle   
       Timeline  

Palisade Operating Cycle Regression Statistics

Arithmetic Mean602.20
Geometric Mean158.82
Coefficient Of Variation175.22
Mean Deviation623.53
Median216.08
Standard Deviation1,055
Sample Variance1.1M
Range4.4K
R-Value(0.19)
Mean Square Error1.1M
R-Squared0.04
Significance0.45
Slope(40.60)
Total Sum of Squares17.8M

Palisade Operating Cycle History

2026 236.07
2025 248.49
2020 216.08
2019 499.44
2018 502.57
2017 521.65
2016 1428.28

About Palisade Bio Financial Statements

Investors use fundamental indicators, such as Palisade Bio's Operating Cycle, to determine how well the company is positioned to perform in the future. Although Palisade Bio's investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Operating Cycle 248.49  236.07 

Currently Active Assets on Macroaxis

When determining whether Palisade Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Palisade Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Palisade Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Palisade Bio Stock:
Check out the analysis of Palisade Bio Correlation against competitors.
For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is there potential for Biotechnology market expansion? Will Palisade introduce new products? Factors like these will boost the valuation of Palisade Bio. Anticipated expansion of Palisade directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Palisade Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.07)
Return On Assets
(0.88)
Return On Equity
(2.29)
The market value of Palisade Bio is measured differently than its book value, which is the value of Palisade that is recorded on the company's balance sheet. Investors also form their own opinion of Palisade Bio's value that differs from its market value or its book value, called intrinsic value, which is Palisade Bio's true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Palisade Bio's market value can be influenced by many factors that don't directly affect Palisade Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Palisade Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Palisade Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Palisade Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.